<DOC>
	<DOCNO>NCT00505167</DOCNO>
	<brief_summary>It well know brain patient Alzheimer 's disease glutamatergic hyperstimulation lead neuronal death . Memantine low affinity antagonist NMDA glutamate receptor . The use drug early phase disease could provide neuroprotective effect delay progression . The effect memantine compare donepezil , prescribed anticholinesterase drug .</brief_summary>
	<brief_title>Memantine Versus Donepezil Early Stages Alzheimer 's Disease</brief_title>
	<detailed_description>On basis excess glutamatergic stimulation , objective demonstrate whether memantine could neuroprotective effect Alzheimer 's disease administer early stage comparison donepezil . The patient would randomize receive one drug . At baseline would evaluate patient clinical standpoint ADAS-cog , neuropsychiatric Inventory scale daily living activities.We also would carry Magnetic Resonance Spectroscopy several area brain ( medial temporal lobe , prefrontal region , cingulate gyrus occipital lobe ) measure concentration N-acetyl-aspartate marker neuronal density.Then treat patient either memantine denepezil 6 month would repeat procedure baseline .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Clinical criterion probable Alzheimer 's disease stag mildtomoderate MiniMental score high 15 point . Previous treatment anticholinesterase drug memantine . Advanced stag disease Lack reliable caregiver . Dementias Alzheimer 's disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Memantine</keyword>
	<keyword>Donepezil</keyword>
	<keyword>Magnetic resonance Spectroscopy</keyword>
	<keyword>randomize trial</keyword>
</DOC>